Philip Morris stock rises despite India keeping IQOS-style device ban, with investors eyeing next catalyst

February 11, 2026
Philip Morris stock rises despite India keeping IQOS-style device ban, with investors eyeing next catalyst

NEW YORK, Feb 11, 2026, 3:37 PM EST — Regular session

  • Philip Morris shares climbed roughly 2% during afternoon trading, beating a flat S&P 500 proxy.
  • India confirmed it has no plans to revise its 2019 ban on e-cigarettes and heated tobacco products.
  • Investors are now eyeing the management’s appearance at the CAGNY conference on Feb. 18.

Philip Morris International shares climbed roughly 2% to $186.30 in afternoon trading Wednesday, after briefly hitting $188.28. This gain outperformed a flat S&P 500 ETF, while consumer staples showed strength; tobacco rivals Altria jumped 2.2% and British American Tobacco added 0.8%.

Shares climbed as investors absorbed a regulatory hit in India, where the health ministry confirmed no plans to ease the 2019 ban on e-cigarettes, which also bans heated tobacco products. This keeps PMI’s IQOS—a “heat-not-burn” device that heats rather than burns tobacco—off a market that sells over 100 billion cigarettes annually. Jefferies analyst Andrei Andon-Ionita called India’s entry “the next leg of the growth story” as other markets slow down. CEO Jacek Olczak slammed the ban as “illogical,” pointing out that traditional cigarettes remain legal. Euromonitor data shows PMI’s cigarette market share in India jumped to 7.6% in 2024, up from 1.75% in 2019. Reuters

The India headline arrives as PMI doubles down on smoke-free products to fuel growth. In its Feb. 6 earnings report, the company revealed full-year net revenue of $40.6 billion, with $16.9 billion coming from its smoke-free segment. It also projected adjusted earnings per share for 2026 between $8.38 and $8.53, a figure that excludes certain one-time items. Philip Morris International

Wednesday’s action on the tape came across as a steady bid rather than a sharp headline-driven spike. Tobacco shares, known for their defensive qualities, held firm alongside a solid consumer-staples sector.

India isn’t just a footnote in the broader narrative. PMI has been betting on smoke-free products as their next big growth driver, but India’s approach highlights how much policy can shape access alongside consumer demand.

That upside, however, isn’t without hurdles. Regulators could clamp down fast, taxes might alter buying habits, and any new products must clear approvals before they gain traction.

Investors must also weigh how sustainable the smoke-free growth will be as competition heats up, particularly in sectors like nicotine pouches and heated tobacco where rivals are heavily investing.

Next week marks a key moment. PMI announced that Olczak and CFO Emmanuel Babeau will present at the Consumer Analyst Group of New York conference on Feb. 18 at 10 a.m. ET. Philip Morris International

Stock Market Today

  • Biotech IPOs Revive as Australian Sector Eyes Major Diseases
    May 19, 2026, 4:17 PM EDT. The Australian biotech sector is recovering from a capital drought with renewed investor interest and upcoming initial public offerings (IPOs). Imunexus, a 'multispecific' drug developer targeting conditions like multiple sclerosis, plans to raise $10-12 million in an IPO within eight weeks. The sector has benefited from eased ASX listing regulations and improved market sentiment. However, capital access remains uneven, favoring companies with existing cash reserves. Recent IPOs such as Saluda Medical and Epiminder faced share price declines post-listing, highlighting market challenges. Imunexus CEO George Kopsidis emphasizes the company's flexible platform, using small proteins called imunexins to enhance drug efficacy, potentially extending drug patent lives or reviving previously failed trials. This marks a significant shift after a post-pandemic slump, as the Australian life sciences industry repositions for growth with a focus on major health conditions including autism, multiple sclerosis, and diabetes.